Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review

GlobalData
54 Pages - GLDATA69607
$125.00

Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. Its portfolio encomppases marketed products for the treatment of multiple sclerosis (MS) and for the intermittent treatment of people with Parkinson’s taking carbidopa or levodopa who experience off episodes. It is also developing a pipeline of neurological therapies addressing a range of disorders, including migraine, MS, heart failure and spinal cord injury. The company sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.

Acorda Therapeutics Inc Key Recent Developments

Feb 13,2020: Acorda Therapeutics provides business update and reports fourth quarter and full year 2019 financial results
Jan 15,2020: Acorda provides 2019 highlights and 2020 guidance at J.P. Morgan Healthcare Conference
Nov 27,2019: Acorda Therapeutics elects John Kelley Chair, Board of Directors
Nov 12,2019: Acorda Therapeutics announces departure of President, International & General Counsel
Nov 04,2019: Acorda provides update for third quarter ended september 30, 2019

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

'

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
Acorda Therapeutics Inc - Key Facts
Acorda Therapeutics Inc - Key Employees
Acorda Therapeutics Inc - Key Employee Biographies
Acorda Therapeutics Inc - Major Products and Services
Acorda Therapeutics Inc - History
Acorda Therapeutics Inc - Company Statement
Acorda Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Acorda Therapeutics Inc - Business Description
Product Category: Ampyra
Overview
Performance
Product Category: Inbrija
Overview
Product Category: Qutenza
Overview
Performance
Product Category: Net Product Revenue
Capital Expenditure
Product Category: Royalty Revenue
Performance
R&D Overview
Acorda Therapeutics Inc - Corporate Strategy
Acorda Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Acorda Therapeutics Inc - Strengths
Acorda Therapeutics Inc - Weaknesses
Acorda Therapeutics Inc - Opportunities
Acorda Therapeutics Inc - Threats
Acorda Therapeutics Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Acorda Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 13, 2020: Acorda Therapeutics provides business update and reports fourth quarter and full year 2019 financial results
Jan 15, 2020: Acorda provides 2019 highlights and 2020 guidance at J.P. Morgan Healthcare Conference
Nov 27, 2019: Acorda Therapeutics elects John Kelley Chair, Board of Directors
Nov 12, 2019: Acorda Therapeutics announces departure of President, International & General Counsel
Nov 04, 2019: Acorda provides update for third quarter ended september 30, 2019
Oct 23, 2019: Acorda Therapeutics implements corporate restructuring, provides third quarter 2019 update
Oct 22, 2019: Acorda launches new tool for people with Parkinson’s to improve communication about off periods
Aug 01, 2019: Acorda provides update for second quarter ended June 30, 2019
Jun 28, 2019: $21.9 Million gene modulation research effort targets influenza pandemics
Jun 03, 2019: Acorda Therapeutics Debuts Art Exhibition inspired by people with Parkinson’s at the 5th World Parkinson Congress
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Acorda Therapeutics Inc, Key Facts
Acorda Therapeutics Inc, Key Employees
Acorda Therapeutics Inc, Key Employee Biographies
Acorda Therapeutics Inc, Major Products and Services
Acorda Therapeutics Inc, History
Acorda Therapeutics Inc, Other Locations
Acorda Therapeutics Inc, Subsidiaries
Acorda Therapeutics Inc, Key Competitors
Acorda Therapeutics Inc, Ratios based on current share price
Acorda Therapeutics Inc, Annual Ratios
Acorda Therapeutics Inc, Annual Ratios (Cont...1)
Acorda Therapeutics Inc, Annual Ratios (Cont...2)
Acorda Therapeutics Inc, Interim Ratios
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Acorda Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Acorda Therapeutics Inc, Performance Chart (2015 - 2019)
Acorda Therapeutics Inc, Ratio Charts
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

$125.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838